Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AVANT Immunotherapeutics, Inc.
NIH Initiates Phase 1 Safety Study of AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine
June 18th, 2008
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced that the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), has initiated a Phase 1 safety study of AVANT's investigational single-dose, oral vaccine designed to offer combined protection against both enterotoxigenic Escherichia coli (ETEC) and cholera. ETEC infection is a major cause of travelers' diarrhea. The study, a randomized double-blind, placebo-controlled, in-patient Phase 1 trial conducted in up to 64 adult volunteers, will examine the safety and immunogenicity of a single dose of...
Source: Vaccine Weekly (2008-06-18)
|
